TF and Alzheimer disease: In addition, serum TF level (Squitti et al., 2010), desaturation level of serum TF-iron (Hare et al., 2015), glycosylated-TF in CSF (Guevara et al., 1998; Van Rensburg et al., 2000; Taniguchi et al., 2008; Shirotani et al., 2011) and serum (Yu et al., 2003) has been proposed as potential AD biomarkers.